Lindis Bloodcare is a renowned brand dedicated to revolutionizing blood management for cancer patients. Their mission is to provide cancer patients with the benefits of autologous blood transfusion, minimizing the side effects associated with allogeneic blood transfusion during oncological surgeries. Lindis Bloodcare has developed the groundbreaking medical device CATUVAB ®, which effectively removes cancer cells from shed blood during surgery, enabling Autologous Blood Transfusion.

This patented technology allows for the reinfusion of autologous erythrocyte concentrates collected during cancer surgeries, providing numerous advantages for the patient. Lindis Bloodcare was founded by two visionary individuals, Dr. Horst Lindhofer, the developer of the first trifunctional antibody approved in Europe, and Dr.

Franzpeter Bracht, a former CEO/CBO of several Life Science companies. With their experienced team, Lindis Bloodcare is dedicated to transforming cancer surgery by optimizing patient outcomes and enhancing their overall well-being. Their commitment to research and development, along with their partnership with international professionals in the field, ensures that Lindis Bloodcare stays at the forefront of innovation in blood management for cancer patients